{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+injection+of+saline+solution&page=2",
    "query": {
      "intervention": "Single injection of saline solution",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+injection+of+saline+solution&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T08:29:34.922Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01264783",
      "title": "Safety and Tolerability of RNS60 Given by IV to Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myocardial Infarct"
      ],
      "interventions": [
        {
          "name": "RNS60",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revalesio Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2011-07",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2011-10-04",
      "last_synced_at": "2026-09-24T08:29:34.922Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01264783"
    },
    {
      "nct_id": "NCT03302754",
      "title": "Precision Dosing of Alemtuzumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "6 Weeks to 30 Years"
      },
      "enrollment_count": 12,
      "start_date": "2017-10-05",
      "completion_date": "2019-03-10",
      "has_results": false,
      "last_update_posted_date": "2019-10-04",
      "last_synced_at": "2026-09-24T08:29:34.922Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03302754"
    },
    {
      "nct_id": "NCT02754830",
      "title": "A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "LY3303560 - IV",
          "type": "DRUG"
        },
        {
          "name": "Saline Solution - IV",
          "type": "DRUG"
        },
        {
          "name": "LY3303560 - SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2016-04-25",
      "completion_date": "2018-07-10",
      "has_results": true,
      "last_update_posted_date": "2023-10-13",
      "last_synced_at": "2026-09-24T08:29:34.922Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02754830"
    },
    {
      "nct_id": "NCT01231971",
      "title": "Alzheimer's Disease Neuroimaging Initiative 2",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mild Cognitive Impairment (MCI)",
        "Alzheimer's Disease (AD)",
        "Significant Memory Concern (SMC)",
        "Early Mild Cognitive Impairment (EMCI)",
        "Late Mild Cognitive Impairment (LMCI)"
      ],
      "interventions": [
        {
          "name": "Florbetapir",
          "type": "DRUG"
        },
        {
          "name": "Flortaucipir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 1182,
      "start_date": "2011-02-14",
      "completion_date": "2017-11-29",
      "has_results": false,
      "last_update_posted_date": "2024-11-21",
      "last_synced_at": "2026-09-24T08:29:34.922Z",
      "location_count": 53,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01231971"
    },
    {
      "nct_id": "NCT05053087",
      "title": "A Study to Compare the Effectiveness of Adductor Canal Pain Catheters Following Total Knee Arthroplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "Ropivacaine Continuous Infusion",
          "type": "DRUG"
        },
        {
          "name": "Ropivacaine Intermittent Bolus",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 60,
      "start_date": "2022-04-13",
      "completion_date": "2023-02-27",
      "has_results": true,
      "last_update_posted_date": "2024-02-22",
      "last_synced_at": "2026-09-24T08:29:34.922Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05053087"
    },
    {
      "nct_id": "NCT06305767",
      "title": "A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intismeran autogene",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Surgery (RC plus PLND)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2024-03-28",
      "completion_date": "2031-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-09-24T08:29:34.922Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305767"
    },
    {
      "nct_id": "NCT02807181",
      "title": "SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Intrahepatic Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Cisplatin-gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sirtex Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2017-02-14",
      "completion_date": "2021-04-29",
      "has_results": true,
      "last_update_posted_date": "2025-05-09",
      "last_synced_at": "2026-09-24T08:29:34.922Z",
      "location_count": 1,
      "location_summary": "Spokane, Washington",
      "locations": [
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02807181"
    },
    {
      "nct_id": "NCT05875948",
      "title": "Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatorenal Syndrome",
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "R2R01",
          "type": "DRUG"
        },
        {
          "name": "Terlipressin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "River 2 Renal Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2023-06-30",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-03",
      "last_synced_at": "2026-09-24T08:29:34.922Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05875948"
    },
    {
      "nct_id": "NCT05482425",
      "title": "Autologous Facial Fat Grafting Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Facial Skin Texture",
        "Facial Skin Pigmentation"
      ],
      "interventions": [
        {
          "name": "Autologous facial fat graft injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 70 Years · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2022-10-17",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-09-24T08:29:34.922Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05482425"
    },
    {
      "nct_id": "NCT02002884",
      "title": "Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cerebral Palsy",
        "Spasticity"
      ],
      "interventions": [
        {
          "name": "IncobotulinumtoxinA (8 Units per kg body weight)",
          "type": "DRUG"
        },
        {
          "name": "IncobotulinumtoxinA (6 Units per kg body weight)",
          "type": "DRUG"
        },
        {
          "name": "IncobotulinumtoxinA (2 Units per kg body weight)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz Pharmaceuticals GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 351,
      "start_date": "2014-03-28",
      "completion_date": "2018-08-28",
      "has_results": true,
      "last_update_posted_date": "2021-08-05",
      "last_synced_at": "2026-09-24T08:29:34.922Z",
      "location_count": 6,
      "location_summary": "Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more",
      "locations": [
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Loxahatchee Groves",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02002884"
    }
  ]
}